Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ -33.52MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
Sector
Industry
History
$ 5.19Close
$ 0.84 - $ 5.94 52-Week Range
Ticker Information
Ticker
GALTCompany Name
GALECTIN THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQGALECTIN THERAPEUTICS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
GALT - EBITDA Historical data
| Date | Depreciation, Amortization & Accretion | Earning Before Interest & Taxes (EBIT) | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) |
|---|---|---|---|
| 6/30/2025 | $ 31K | $ -33.55M | $ -33.52M |
| 3/31/2025 | $ 38K | $ -38.96M | $ -38.92M |
| 12/31/2024 | $ 37K | $ -41.51M | $ -41.47M |
| 9/30/2024 | $ 36K | $ -40.41M | $ -40.38M |
| 6/30/2024 | $ 35K | $ -43.9M | $ -43.87M |
| 3/31/2024 | $ 10K | $ -41.26M | $ -41.25M |
| 12/31/2023 | $ 33K | $ -41.89M | $ -41.86M |
| 9/30/2023 | $ 32K | $ -43.07M | $ -43.04M |
| 6/30/2023 | $ 31K | $ -38.19M | $ -38.15M |
| 3/31/2023 | $ 54K | $ -39.1M | $ -39.05M |
Key Performance Insights, Last 5 Years
- GALECTIN THERAPEUTICS INC's latest trailing twelve months (TTM) EBITDA stands at $ -20.63M.
- Over the past 5 years, GALECTIN THERAPEUTICS INC's average EBITDA has been $ -35.04M.
- The median EBITDA for GALECTIN THERAPEUTICS INC during this period was $ -36.06M
- GALECTIN THERAPEUTICS INC reached its highest EBITDA over the past 5 years at $ -20.63M.
- The lowest EBITDA recorded by GALECTIN THERAPEUTICS INC in the same timeframe $ -43.87M
Similar metrics to EBITDA:
- Depreciation, Amortization & Accretion - [Cash Flow Statement] A component of operating cash flow [NCFO] representing the aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a non-cash item, the net amount is added back to net income when calculating cash provided by operations.
- Enterprise Value over EBITDA - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest, taxes, depreciation, and amortization [EBITDA].
- EBITDA per Share - [Calculation] The amount of earnings before interest, taxes, depreciation, and amortization attributed to each share, calculated as [EBITDA] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
- Earning Before Interest & Taxes (EBIT) - [Income Statement] Earnings before interest and taxes measures a company's net income [NetInc] prior to the deduction of interest [IntExp] and tax expenses [TaxExp].
- EBITDA Margin - [Calculation] A company’s [EBITDA] as a percentage of [Revenue]. Measures how much earnings a company produces for each dollar of revenue generated before interest, taxes, depreciation and amortization.
Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].EBIT + DepAmor
(=) EBITDA EBITDA for GALECTIN THERAPEUTICS INC is calculated as follows: EBIT [ $ -20.66M ] + DepAmor [ $ 36K ]
(=) EBITDA [ $ -20.63M ] GALT - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years
$ -43.87M
Minimum
Jun 30, 2024
$ -20.63M
Maximum
Sep 30, 2020
$ -35.04M
Average
$ -36.06M
Median
EBITDA Benchmark AnalysisMarket
The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.77M with a standard deviation of $ 166.95M.
The following table provides additional summary stats:
EBITDA in the Market:
| filtered constituents | 3.25K |
|---|---|
| min | $ -493.3M |
| max | $ 590.6M |
| average | $ 58.77M |
| median | $ 8.83M |
| std | $ 166.95M |